Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (HJLI) on July 26, 2019. The filing serves as a Regulation FD disclosure regarding clinical trial updates for the company's VenoValve device. The registrant is an emerging growth company incorporated in Delaware with its principal offices in Irvine, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial disclosures and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the presentation of new 90-day data from the company's first-in-man VenoValve study. The data was presented by Dr. Jorge Hernando Ulloa, the principal investigator, at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean in Bogota, Colombia.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the clinical study. The primary disclosure is the release of clinical data, with the full presentation and press release attached as Exhibits 99.1 and 99.2.
Investor Verification Checklist
- Verify the specific clinical outcomes and safety data contained in the attached presentation (Exhibit 99.1).
- Review the full press release (Exhibit 99.2) for details on the study's scope and implications.
- Confirm the status of the VenoValve regulatory pathway following the 90-day data release.
- Note that the company name in the metadata (Envveno Medical Corp) differs from the registrant name in the filing (Hancock Jaffe Laboratories, Inc.).